Cyclobutane analgesics



United States Patent 3,004,889 CY CLOBUTANE ANALGESICS Samuel Kuna, Westfield, and Armin G. Wilson, Highland Park, N.I., assignors to Bristol-Myers Company, New York, N.Y., a corporation of Delaware No Drawing. Filed May 16, 1960, Ser. No. 29,153 17 Claims. (Cl. 167-65) This invention relates to therapeutic compositions. More specifically, this invention relates to compositions containing certain cyclobutane derivatives which can be used as analgesics or as central nervous system stimulants.

The therapeutic compositions of this invention comprise, as the therapeutically active agent, a cyclobutane derivative having the following generic formula:

wherein each of R R R and R is a hydrocarbon radical containing up to about 8 carbon atoms. Illustratively, each of the hydrocarbon'radicals can be a straight or branched chain alkyl; an unsaturated hydrocarbon, such as a straight or branched chain olefin; a cycloalkyl; the phenyl radical; or the benzyl radical. All of the hydrocarbon radicals on the cyclobutane derivative as represented by the above generic formula need not be the same; although it is preferred that each of R and R, be the same radical and that each of R and R be the same radical and differing from R, and R or that all the hydrocarbon radicals of R R R and R; be the same.

Illustrative of specific compounds suitable for this invention there can be mentioned: 2,2,4,4-tetramethyl 1,3- cyclobutanediol; 2,2,4,4-tetraethyl 1,3-cyclobutanediol; 2,2,4,4-tetraisopropyl 1,3-cyclobutanediol; 2,2,4,4.-tetrapropyl 1,3-cyclobutanediol; 2,2,4,4-tetra (tertiary butyl) 1,3-cyclobutanediol; 2,2,4,4-tetrabuty-l 1,3-cyclobutane diol; 2,2,4,4-tetra n-pentyl) 1,3-cyclobutanediol; 2,2,4,4- tetraphenyl 1,3-cyclobutanediol; 2,2,4,4-tetracyclohexyl 1,3-cyclobutanediol; 2,2,4,4-tetrabenzyl 1,3-cyclobutanediol; 2,2,4,4-tetrally l 1,3-cyclobutanediol; 2,2,4,4-tetra(lbutenyl) 1,3-cyclobutanediol; 2,2,4,4tetra(1-heptenyl) 1,3-cyclobutanediol; 2,4-dimethyl 2,4-diethy1 1,3-cyelobutanediol; 2,4-dimethyl 2,4-dipropyl 1,3-cyclobutanediol; 2,4-diethyl 2,4 diisopropyl 1,3-cyclobutanediol; 2,4-diethyl 2,4-di(tertiary butyl) 1,3-cyclobutanediol; 2,4-dimethyl 2,4-diphenyl 1,3-cyclobutanediol; 2,4-dimethyl 2,4-dibenzyl 1,3-cyclobutanediol; 2,4-dicyclohexyl 2,4-diethyl 1,3-cyclobut-anediol; 2,4-diallyl 2,4-diethyl 1,3-cyclobutanediol; and Z-methyl 2-ethyl 4-propyl 4-(n-pentyl) 1,3-cyc1obutanediol.

The cyclobutane derivatives of this invention can be prepared by a number of methods including those set forth in U.S. Patent 2,936,324, which issued on May 10, 1960; and Organic Reactions, vol. III, pagm 108 to 136, edited by Roger Adams and published by John Wiley and Sons, Inc. (1946).

The cyclobutanediols of this invention can be administered by the conventional methods, the conventional types of unit dosages or with the conventional pharmaceutical carriers to produce an analgesic or central nervous system stimulant efiect in human beings and animals. Oral administration by the use of tablets, capsules or in liquid form such as suspensions, or emulsions is particularly advantageous. When formed into tablets, the conven- Patented Oct. 17, 1961 tional binding and disintegrating agents used in therapeutic unit dosages can be employed. Illustrative of binding agents there can be mentioned glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate and talc. Illustrative of disintegrating agents there can be mentioned corn starch, keratin, colloidal silica and potato starch. When administered as liquids the conventional liquid carriers can be used.

The unit dosage or therapeutically efiective quantity of the cyclobutanediols of this invention for human beings can vary over wide limits such as that of'about 0.1 of a grain to about 20 grains or more such as over 50 grains. The upper limit is limited only by the degree of efiect desired and economic considerations. For oral administration it is preferable to employ from about 1 to about 10 grains of the therapeutic agent per unit dosage. It is indicated from animal experiments that about 1 to about 10 grain dosages administered orally four times daily as needed will provide a preferred daily dosage. Of course, the dosage of the particular therapeutic agent used can vary considerably, such as the age of the patient and the degree of therapeutic effect desired. Each unit dosage form of the novel therapeutic compounds can contain from about 5% to about and preferably from about 10% to 80% of the novel therapeutic agents by weight of the entire composition with the remainder comprising conventional pharmaceutical carriers. By the term pharmaceutical carrier we intend to include nontherapeutic materials which are conventionally used with unit dosages and includes fillers, diluents, binders, lubricants, disintegrating agents and solvents. Of course, it is possible to administer the novel therapeutics, i.e., the pure compounds, without the use of a pharmaceutical carrier. When the therapeutic agents of this invention are employed for one of their enumerated utilities such as analgesics for the amelioration of pain such as the common headache, mild rheumatism and the like, they can be administered either prior to or after the onset of the discomfort.

The invention is illustrated by the following examples of suitable therapeutic compositions in unit dosage form, although it is not intended that the compositions or dosages be limited by any of the proportions, amounts, types of carriers, or dosage units set forth therein.

EXAMPLE I A suitable formulation of tablets consists of:

Grams (1) 2,2,4,4-tetraethyl 1,3-cyclobutanediol 12.5 (2) Lactose 80 (3) Starch 5 (4) Magnesium stearate 2 The 2,2,4,4-tetraethyl 1,3-cyclobutanediol, lactose and starch are thoroughly mixed and granulated. For tabletting, the magnesium stearate is added, mixed with the granules, and the mixture tabletted on a rotary press. Use of this procedure produces tablets each containing mg. of the active therapeutic agent.

' V 3 The 2,4-dimethy1 2,4-die thy1 1,3-cyclobutanediol mannitol and starch are thoroughly mixed and granulated. For tabletting, the magnesium stearate is added, mixed with granules, and the mixture tabletted on a rotary press. Use of this procedure produces 100 tablets each containing 250 mg. of the active therapeutic agent.

EXAMPLES Another suitable formulation of tablets consists of:

a Grams (I) 2 ,Z,4,4-tefra isbProp/1' 1,3 -'cycl6b1itanediol 25 g n-Lactose a 1 70 (3) Dextr'in a a 10 (4:):fiyd'1ogriateclvegetable oil' 0.5 (5) Talc 2V T he 2,2,4,'4-tetraisopropyl 1,3-cyclobutanedio1 b-lactose, and dextrin' are thoroughly mixed and granulated. For tabletting, the hydrogenated vegetable oil and? talc are added, mixed with the granules, airdthe mixture tabletted on arotary press. Use of this procedure produces 200 tablets of 125 mg. of active th'ere'apeutic agent. t; Either the cis isomer, the trans isomer or mixtures of these two isomers of the cyclobutane'diols of this invention ,eanb'e employed: for their. therapeutic efiectsl' What is claimed is: v

- 1. An analgesic compositionin' unit dosageform comprising a significant quantity of a pharmaceutical carrier and from about 0.1 grain to about grains of a cyclobutane derivative having the following generic formula:

i 11 7| 5 Ra-C- 0H 'H0jd-o--R1' H R2 7 wherein each of R R R andR; is a hydrocarbon radical containing up to about 8 carbon atoms.

2.7 The analgesic composition of claim 1 wherein each of thehydrocarbon radicals containing up to about 8 carbon atoms is a member selected from the group con sisting of an alkyl radical, an alkylen'e radical, the phenyl radical, a cyclo'alkyl radical having from 4 to 6 carbon atoms-and the benzyl radical.

3; The analgesic composition of claim 1 wherein each of R R R and R is an alkyl radical. V

' '4. The analgesic composition of'claiin 1 wherein each of R R R and R is the phenyl radical.

5-. An analgesic-composition in unit dosage form comprising a significantquantity of a pharmaceutical carrier anti-from about 1 grain to about 10 grains of a cyclobutane derivative having the following generic formula:

H In, 7

wherein each in 11 ,19,

- '4 wherein each of R R R and R4 is an alkyl radical containing from 1 to 4 carbon atoms.

6. The analgesic composition of claim 5 wherein the cyclobutane derivative is 2,2,4,4-tetramethyl 1,3-cyclobutanediol.

7. The analgesic composition of claim 5 wherein the cyclobutane derivative is 2,4-diethy1 2,4-dimethy1 1,3-

cyclobutanediol.

8. The analgesic composition of claim 5 wherein the cyclobutane derivative is 2,2,4,4-tetraethyl 1,3-cyc1obutanediol. v p p H p 9. The analgesic composition of-claim' S'Wherein the cyclobutane derivative is 2,'2',4',4-'tensi0prepy1 Lil-cyclobutanediol. V I

10'. A method for inducing analgesic which comprises administering to an ahimal, including a human, an analgesically eifective quantity of a cyclobutane derivative having'the following generic formula:

' 7 R4 HI R:-( 3--OH no 'o-' R1 it I wherein each of R R R and R is a hydrocarbon radical containing up to about 8 carbon atoms.

11. The method of claim 10 wherein each of the hydrocarbon radicals containing up to about 8 carbon atoms is a member selected from the group consisting of an alkyl radical, an alkylen'e radical the phenyl radical, a cycloalkyl radical having from 4 to 6 carbon atoms andthe ben'zyl' radical. Q

12. The method of claim 10 wherein 13, A method for inducing analgesic which comprises administering to' an animal, including a'huma'n, from about 0.1 to about 20' grains per unit dosage of a cyclobutane derivative having the following generic formula:

1 H RaCd-on Ho-o- 3-R1 7 R and R is an alkyl radical containing from 1 to 4 carbon atoms.

14. The method of claim 13 wherein the cyclobutane derivative is 2,2,4,4-tetramefth'y'l l,3'-c'clobutanediol.

1-5. The method of claim 13 wherein the cyclobutane derivative is 2,4-dithylj2A-dim'eth'yl 1 ,3-cyclobutanediol. A16. The method of claim 13 wherein the cyclobutane derivative is 2,2,4,4'-tetrathyl l,3-cyclobutanediol,

17. The method of claim l-3flwhefein the cyclobutane derivative is 2,2,4,4-t'etrai'sopropyl 1,3-cyclobuta'nediol.

7 References Cited inithe file of this patent UNITED STATES PATENTS Hasek et a1. May 10, 1960 UNITED STATES- PATENT. OFFICE CERTIFICATE OF CORRECTION Patent N09 3,004 889 October 17 1961- Samuel Kuna et al.

It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below Column 4 lines 15 and 34 for "analgesicH each occurrence read analgesia Signed and sealed this 3rd day of April 1962 (SEAL) Attest:

ERNEST W. SWIDER DAVID L. LADD Attesting Officer Commissioner of Patents 

1. AN ANALGESIC COMPOSITION IN UNIT DOSAGE FORM COMPRISING A SIGNIFICANT QUANTITY OF A PHARMACEUTICAL CARRIER AND FROM ABOUT 0.1 GRAIN TO ABOUT 20 GRAINS OF A CYCLOBUTANE DERIVATIVE HAVING THE FOLLOWING GENERIC FORMULA: 